Recent improvement of survival prognosis after pulmonary metastasectomy and advanced chemotherapy for patients with colorectal cancer

Nakajima, Jun; Iida, Tomohiko; Okumura, Sakae; Horio, Hirotoshi; Asamura, Hisao; Ozeki, Yuichi; Ikeda, Norihiko; Matsuguma, Haruhisa; Chida, Masayuki; Otsuka, Hajime; Kawamura, Masafumi

doi:10.1093/ejcts/ezw401

Cited by 23 publications

(20 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 Our results demonstrate that even a patient cohort limited to SLLM could show favorable long-term outcomes after resection based on accurate candidate selection; this might also be associated with modern advances in systemic therapies and perioperative management. 29 However, some researchers have indicated that SLLM are unlikely to warrant complete metastasectomy because of their deleterious impact on the prognosis, 19 which might be attributable to patient populations with a heterogeneous tumor biology. Oncologic subclassification in patients with SLLM would be further needed to extend the surgical indications in the era of multidisciplinary approaches to metastatic colorectal cancer.…”

Section: Discussionmentioning

confidence: 99%

Oncological benefit of complete metastasectomy for simultaneous colorectal liver and lung metastases

Matsumura

Yamashita

Ishizawa

et al. 2020

The American Journal of Surgery

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Oncological benefit of complete metastasectomy for simultaneous colorectal liver and lung metastases

Matsumura

Yamashita

Ishizawa

et al. 2020

The American Journal of Surgery

Self Cite

View full text Add to dashboard Cite

“…Only one randomized study comparing PM versus continued active monitoring has been published, although it was discontinued due to poor recruitment rate, thus making the results inconclusive 11 . Moreover, the role of adjuvant chemotherapy for patients treated with PM has been controversial, with studies showing conflicting results 12–14 . Therefore, further research is needed to identify additional prognostic and predictive factors for improved selection of patients with mCRC who will benefit from surgery and adjuvant chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of RBM3 expression in surgically treated colorectal lung metastases and paired primary tumors

Viðarsdóttir

Siesing

Nodin

et al. 2021

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background The lungs are the second most common site of metastases in colorectal cancer (CRC). The aim of this study was to investigate prognostic factors, including RNA‐binding motif protein 3 (RBM3) expression, in patients with CRC treated with pulmonary metastasectomy (PM). Methods The cohort included all patients treated with PM at Skåne University Hospital, Lund, Sweden, from 2000 to 2014. Clinicopathological, treatment, and survival data were collected. Immunohistochemical staining of RBM3 was evaluated on tissue microarrays with samples from all lung metastases and a subset of paired primary tumors. Kaplan–Meier analysis and Cox proportional hazards modeling were applied to examine the associations of investigative factors with overall survival (OS) and recurrence‐free survival. Results In total, 216 patients with a primary tumor in the rectum (57%), left colon (34%), or right colon (9%) underwent PM. The 5‐year OS rate was 56%. Age > 60 years, more than one metastasis, size of metastasis > 3 cm, disease‐free interval < 24 months, low RBM3 score in the lung metastasis, and no adjuvant chemotherapy following PM were prognostic factors for shorter OS. Conclusions Several prognostic factors, including RBM3 expression, may be of aid in selecting CRC patients with lung metastases for PM as well as adjuvant therapy.

show abstract

“…China had 245,000 new CRC cases and 139,000 deaths from CRC in 2012, which made it the fifth most common cancer in men and the fourth in women (Gu et al, 2018). Although great advancements have been made in surgical procedures and adjuvant therapies, the overall survival of CRC patients is still poor, especially that of patients at later stages of disease (Fang et al, 2013; Nakajima et al, 2017). However, many CRC patients are initially diagnosed at advanced stages, since early-stage CRC is either asymptomatic or presents with non-specific symptoms (Clarke & Feuerstein, 2018; Hall et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Association and diagnostic value of serum SPINK4 in colorectal cancer

Xie

et al. 2019

PeerJ

View full text Add to dashboard Cite

The role of serum serine peptidase inhibitor, Kazal type 4 (SPINK4), in colorectal cancer (CRC) is largely unknown. This study aimed to explore the association and diagnostic value of serum SPINK4 in CRC. A total of 70 preoperative CRC patients, 30 postoperative CRC patients, 30 gastric cancer patients, and 30 healthy controls were enrolled. Using enzyme-linked immunosorbent assays, we found that the serum SPINK4 level was significantly increased in preoperative CRC compared with postoperative CRC patients, gastric cancer patients, and healthy controls (p < 0.05). The serum SPINK4 level was remarkably elevated in colon cancer compared with rectal cancer and was enhanced in the M1 stage compared with the M0 stage (p < 0.05). The area under the receiver operating characteristic curve of serum SPINK4 level in the diagnosis of CRC was 0.9186, with a sensitivity and specificity of 0.886 and 0.900, respectively, and a cut-off value of 2.065. There was no significant difference between high and low expression of serum SPINK4 regarding the overall survival time and disease-free survival (p > 0.05). This study demonstrated that the serum SPINK4 level increased in CRC and was associated with the location and distant metastasis of CRC. It had a high diagnostic value in CRC but was not associated with the survival of CRC patients.

show abstract

Recent improvement of survival prognosis after pulmonary metastasectomy and advanced chemotherapy for patients with colorectal cancer

Abstract: Survival rates of patients after pulmonary metastasectomy for colorectal cancer metastasis who underwent chemotherapy have increased over the years. It implies that newer chemotherapy regimens might have had a positive impact on these patients.

Cited by 23 publications

References 21 publications

Oncological benefit of complete metastasectomy for simultaneous colorectal liver and lung metastases

Oncological benefit of complete metastasectomy for simultaneous colorectal liver and lung metastases

Clinical significance of RBM3 expression in surgically treated colorectal lung metastases and paired primary tumors

Association and diagnostic value of serum SPINK4 in colorectal cancer

Contact Info

Product

Resources

About